Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary systemic carnitine deficiency: I. Carnitine biosynthesis.

C J Rebouche, A G Engel

    Neurology
    |July 1, 1981
    PubMed
    Summary

    Patients with primary systemic carnitine deficiency showed altered carnitine metabolism. This study found their carnitine deficiency is not due to issues in synthesis or breakdown.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.

    The Lancet. Neurology·2015
    Same author

    Marked phenotypic variability in two siblings with congenital myasthenic syndrome due to mutations in MUSK.

    Journal of neurology·2013
    Same author

    Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship: Correction.

    Neuromuscular disorders : NMD·2012
    Same author

    Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

    Neurology·2011
    Same author

    Myasthenic syndrome caused by plectinopathy.

    Neurology·2011
    Same author

    Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients.

    Neurology·2009

    Area of Science:

    • Biochemistry
    • Metabolic Disorders
    • Human Physiology

    Background:

    • Primary systemic carnitine deficiency is a rare metabolic disorder.
    • Carnitine plays a crucial role in fatty acid metabolism.
    • Understanding carnitine's metabolic fate is key to diagnosing and managing deficiency.

    Purpose of the Study:

    • To investigate the metabolic fate of carnitine in patients with primary systemic carnitine deficiency.
    • To determine if defective biosynthesis or abnormal degradation causes the deficiency.
    • To compare carnitine kinetics between patients and healthy controls.

    Main Methods:

    • Administration of radiolabeled [Methyl-3H]epsilon-N-trimethyl-L-lysine to patients and controls.
    • Monitoring of labeled carnitine appearance and radioactivity in blood and urine over time.
    • Analysis of radioactive metabolites in urine.

    Main Results:

    • Labeled carnitine was rapidly absorbed and excreted in both patients and controls.
    • Urinary carnitine radioactivity peaked early (2-6 hours) in most subjects.
    • One patient exhibited an unusual serum carnitine radioactivity profile, peaking at 48 hours.
    • Comparable amounts of other radioactive metabolites were found across all subjects.
    • Excretion of labeled L-carnitine varied between patients and controls.

    Conclusions:

    • Primary systemic carnitine deficiency in these patients is not caused by defective carnitine biosynthesis.
    • Abnormal degradation of carnitine does not appear to be the cause of the deficiency.
    • Carnitine metabolism is altered in primary systemic carnitine deficiency, suggesting other regulatory mechanisms may be involved.

    Related Experiment Videos